← Leaderboards
Mark T. Miedel
University Of Pittsburgh At Pittsburgh
$2,142,086
Attributed
$2,789,260
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,891,432 · 5
By mechanism
U2C$3,102,172 · 1
R01$1,294,349 · 1
UH2$865,037 · 1
UH3$477,000 · 1
F32$152,874 · 1
Top collaborators
- Alejandro Soto-Gutierrez4 shared
- Mark E Schurdak2 shared
- D. Lansing Taylor2 shared
- Lawrence A Vernetti2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Carlos Cruchaga$41,433,350
- Jaideep Behari$4,660,334
- Reza Zarnegar$10,558,814
- Mark E Schurdak$7,669,687
- Joseph M Zmuda$12,126,344
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationResponsePathway InteractionsHepatic Acinus StructureDrug IndustryCellsInduced Pluripotent Stem CellPrecision MedicineCohortDrug DiscoveryNon-Alcoholic Fatty Liver DiseaseBiomimeticsLiverMicrophysiology SystemHepatocyteDrug TestingBiological ModelsProteinsInvestmentsDisease PhenotypeNational Center For Advancing Translational SciencesHuman DiseaseAnimal ModelCollaborations
Grant awards (11)
Qualification of Patient-Derived Biomimetic Liver MPS as Drug Discovery Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing and Clinical Trial Cohort Selection$1,540,258
U2C · FY2025 · TR
Implementing A QSP Platform to Predict and Test Drugs for Metabolic Associated Fatty Liver Disease Genetic Variants in an iPSC-cell Based Human Biomimetic Liver Microphysiology System$598,763
R01 · FY2025 · DK · contact PI
Re-engineering a human 3D liver tissue model for non-alcoholic fatty liver disease for drug screening$238,500
UH3 · FY2025 · TR · contact PI
Qualification of Patient-Derived Biomimetic Liver MPS as Drug Discovery Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing and Clinical Trial Cohort Selection$1,561,914
U2C · FY2024 · TR
Implementing A QSP Platform to Predict and Test Drugs for Metabolic Associated Fatty Liver Disease Genetic Variants in an iPSC-cell Based Human Biomimetic Liver Microphysiology System$695,586
R01 · FY2024 · DK · contact PI
Re-engineering a human 3D liver tissue model for non-alcoholic fatty liver disease for drug screening$238,500
UH3 · FY2024 · TR · contact PI
Re-engineering a human 3D liver tissue model for non-alcoholic fatty liver disease for drug screening$428,360
UH2 · FY2023 · TR · contact PI
Re-engineering a human 3D liver tissue model for non-alcoholic fatty liver disease for drug screening$436,677
UH2 · FY2022 · TR · contact PI
The Role of Intracellular Serpins in the Regulation of Necrosis$53,942
F32 · FY2012 · DK · contact PI
The Role of Intracellular Serpins in the Regulation of Necrosis$51,326
F32 · FY2011 · DK · contact PI
The Role of Intracellular Serpins in the Regulation of Necrosis$47,606
F32 · FY2010 · DK · contact PI